Glioblastoma and Other Malignant Gliomas: A Clinical Review, JAMA, vol.310, issue.17, pp.1842-50, 2013. ,
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol (Berl), vol.131, issue.6, pp.803-823, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01479018
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, Lancet Oncol, vol.10, issue.5, pp.459-66, 2009. ,
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma, N Engl J Med, vol.352, issue.10, pp.987-96, 2005. ,
Pseudoprogression and Pseudoresponse in the Management of High-Grade Glioma : Optimal Decision Timing According to the Response Assessment of the Neuro-Oncology Working Group, J Korean Neurosurg Soc, vol.55, issue.1, pp.5-11, 2014. ,
Pseudoprogression: Relevance With Respect to Treatment of High-Grade Gliomas, Curr Treat Options Oncol, vol.12, issue.3, p.240, 2011. ,
Neuro-Oncology: Current Concepts and Emerging Therapeutics, Neurotherapeutics, vol.14, issue.2, pp.253-258, 2017. ,
DOI : 10.1007/s13311-017-0529-8
URL : https://link.springer.com/content/pdf/10.1007%2Fs13311-017-0529-8.pdf
Predicting Glioblastoma Recurrence by Early Changes in the Apparent Diffusion Coefficient Value and Signal Intensity on FLAIR Images, Am J Roentgenol, vol.208, issue.1, pp.57-65, 2016. ,
Improving the utility of 1H-MRS for the differentiation of glioma recurrence from radiation necrosis, J Neurooncol, vol.133, issue.1, pp.97-105, 2017. ,
The diagnostic performance of perfusion MRI for differentiating glioma recurrence from pseudoprogression, Medicine ,
Amino acid PET in neuro-oncology: applications in the clinic, Expert Rev Anticancer Ther, vol.17, issue.5, pp.395-402, 2017. ,
The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy, NeuroImage Clin, vol.13, pp.386-94, 2017. ,
Impact of 3,4Dihydroxy-6-18F-Fluoro-l-Phenylalanine PET/CT on Managing Patients with Brain Tumors: The Referring Physician's Perspective, J Nucl Med, vol.53, issue.3, pp.393-401, 2012. ,
Clinical impact of 18F-FDOPA PET in the differential diagnosis between recurrence and radiation necrosis in brain tumors, J Nucl Med, vol.58, pp.75-75, 2017. ,
18FFDOPA PET for Differentiating Recurrent or Progressive Brain Metastatic Tumors from Late or Delayed Radiation Injury After Radiation Treatment, J Nucl Med, vol.55, issue.1, pp.30-36, 2014. ,
Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients, Neuro-Oncol, vol.16, issue.4, pp.603-612, 2014. ,
18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy, J Nucl Med Off Publ Soc Nucl Med, vol.47, issue.6, pp.904-915, 2006. ,
18F] FDOPA standardized uptake values of brain tumors are not exclusively dependent on LAT1 expression, PloS One, vol.12, issue.9, p.184625, 2017. ,
The role of LAT1 in 18F-DOPA uptake in malignant gliomas, J Neurooncol, vol.111, issue.1, pp.11-19, 2013. ,
Factors affecting 18F FDOPA standardized uptake value in patients with primary brain tumors after treatment, Nucl Med Biol, vol.42, issue.4, pp.355-364, 2015. ,
Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas, J Nucl Med Off Publ Soc Nucl Med, vol.51, issue.10, pp.1532-1540, 2010. ,
, Correlation of SUV-Derived Indices With Tumoral, Clinical Nuclear Medicine
, Clinical Nuclear Medicine
IDH mutation is paradoxically associated with higher 18F-FDOPA PET uptake in diffuse grade II and grade III gliomas, Eur J Nucl Med Mol Imaging, vol.44, issue.8, pp.1306-1317, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01735109
Évaluation préopératoire comparative de 43 gliomes de grade II et III par TEP au 18F-FDG et à la 18F-DOPA : corrélation aux données histologiques et moléculaires. Médecine Nucl, vol.40, pp.285-96, 2016. ,
Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma, Clin Nucl Med, vol.42, issue.5, pp.341-348, 2017. ,
Targeting epidermal growth factor receptor co-dependent signaling pathways in glioblastoma, Wiley Interdiscip Rev Syst Biol Med ,
Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance, Neoplasia N Y N, vol.12, issue.9, pp.675-84, 2010. ,
18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: Initial experience, Eur J Radiol, vol.71, issue.2, pp.242-250, 2009. ,
18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT, Eur J Nucl Med Mol Imaging, vol.40, issue.7, pp.1025-1060, 2013. ,
Impact of 3,4Dihydroxy-6-18F-Fluoro-l-Phenylalanine PET/CT on Managing Patients with Brain Tumors: The Referring Physician's Perspective, J Nucl Med, vol.53, issue.3, pp.393-401, 2012. ,
Metabolic Assessment of Gliomas Using 11C-Methionine, [18F] Fluorodeoxyglucose, and 11C-Choline PositronEmission Tomography, Am J Neuroradiol, vol.29, issue.6, pp.1176-82, 2008. ,
Diagnosis of Brain Tumors Using Amino Acid Transport PET Imaging with 18F-fluciclovine: A Comparative Study with L-methyl11C-methionine PET Imaging, Asia Ocean J Nucl Med Biol, vol.5, issue.2, pp.85-94, 2017. ,
Prognostic role of Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified primary and recurrent glioblastomas, Clin Cancer Res, 2017. ,
An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell, vol.17, p.98, 2010. ,
Stem cell signature in glioblastoma: therapeutic development for a moving target, J Neurosurg, vol.122, issue.2, pp.324-354, 2014. ,
Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3, Proc Natl Acad Sci, vol.110, issue.21, pp.8644-8653, 2013. ,
Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer. J Nucl Med Off Publ Soc Nucl Med, vol.58, pp.569-76, 2017. ,
The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer, Oncotarget, vol.8, issue.20, pp.33736-33780, 2017. ,
Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma, PLOS ONE, vol.12, issue.4, p.175622, 2017. ,
Glioblastome du sujet âgé : état de l'art. Bull Cancer (Paris), vol.102, pp.277-86, 2015. ,
Prognostic value of epidermal growth factor receptor amplification and EGFRvIII in glioblastoma: meta-analysis, Acta Neurol Scand, vol.132, issue.5, pp.310-332, 2015. ,
Expression of EGFRvIII in Glioblastoma: Prognostic Significance Revisited, Neoplasia N Y N, vol.13, issue.12, pp.1113-1134, 2011. ,
EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma, Lancet Oncol, vol.15, issue.9, pp.395-403, 2014. ,
Paradoxical relationship between degree of EGFR amplification and outcome in glioblastomas, Am J Surg Pathol, vol.36, issue.8, pp.1186-93, 2012. ,
Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM, Neurology, vol.84, issue.7, pp.710-719, 2015. ,
Prognostic value of posttreatment metabolic tumor volume from 11C-methionine PET/CT in recurrent malignant glioma, Neurosurg Rev, vol.40, issue.2, pp.223-232, 2017. ,
, Annexe 2. Echelle visuelle selon Lizarraga pour différencier récidive et radionécrose
, Annexe 3. Voies de signalisation affectées par les amplifications géniques dans les GB
, Annexe 5. Sous-types moléculaires de GB selon la classification de Verhaak, 2010.